The direct and indirect costs of both overweight and obesity: a systematic review by Dee A et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
Dee A, Kearns K, O'Neill C, Sharp L, Staines A, O'Dwyer V, Fitzgerald S, Perri I. 
The direct and indirect costs of both overweight and obesity: a systematic 
review. BMC Research Notes 2014, 7(1), 242. 
 
 
Copyright: 
© 2014 Dee et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is 
properly credited. The Creative Commons Public Domain Dedication waiver 
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, 
unless otherwise stated.  
DOI link to article: 
http://dx.doi.org/10.1186/1756-0500-7-242 
Date deposited:   
26/06/2015 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Dee et al. BMC Research Notes 2014, 7:242
http://www.biomedcentral.com/1756-0500/7/242RESEARCH ARTICLE Open AccessThe direct and indirect costs of both overweight
and obesity: a systematic review
Anne Dee1*, Karen Kearns2, Ciaran O’Neill3, Linda Sharp4, Anthony Staines5, Victoria O’Dwyer2,
Sarah Fitzgerald2 and Ivan J Perry2Abstract
Background: The rising prevalence of overweight and obesity places a financial burden on health services and on
the wider economy. Health service and societal costs of overweight and obesity are typically estimated by top-
down approaches which derive population attributable fractions for a range of conditions associated with increased
body fat or bottom-up methods based on analyses of cross-sectional or longitudinal datasets. The evidence base of
cost of obesity studies is continually expanding, however, the scope of these studies varies widely and a lack of
standardised methods limits comparisons nationally and internationally. The objective of this review is to contribute
to this knowledge pool by examining direct costs and indirect (lost productivity) costs of both overweight and
obesity to provide comparable estimates. This review was undertaken as part of the introductory work for the Irish
cost of overweight and obesity study and examines inconsistencies in the methodologies of cost of overweight
and obesity studies. Studies which evaluated the direct costs and indirect costs of both overweight and obesity
were included.
Methods: A computerised search of English language studies addressing direct and indirect costs of overweight
and obesity in adults between 2001 and 2011 was conducted. Reference lists of reports, articles and earlier reviews
were scanned to identify additional studies.
Results: Five published articles were deemed eligible for inclusion. Despite the limited scope of this review there
was considerable heterogeneity in methodological approaches and findings. In the four studies which presented
separate estimates for direct and indirect costs of overweight and obesity, the indirect costs were higher,
accounting for between 54% and 59% of the estimated total costs.
Conclusion: A gradient exists between increasing BMI and direct healthcare costs and indirect costs due to
reduced productivity and early premature mortality. Determining precise estimates for the increases is mired by the
large presence of heterogeneity among the available cost estimation literature. To improve the availability of quality
evidence an international consensus on standardised methods for cost of obesity studies is warranted. Analyses of
nationally representative cross-sectional datasets augmented by data from primary care are likely to provide the
best data for international comparisons.
Keywords: Direct costs, Health care costs, Indirect costs, Lost productivity costs, Overweight, Obesity* Correspondence: anne.dee1@hse.ie
1Department of Public Health, Health Service Executive West, Mount Kennett
House, Henry Street, Limerick, Ireland
Full list of author information is available at the end of the article
© 2014 Dee et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Dee et al. BMC Research Notes 2014, 7:242 Page 2 of 9
http://www.biomedcentral.com/1756-0500/7/242Background
The prevalence of overweight (BMI > 25 Kg/m2) and obes-
ity (BMI > 30 Kg/m2) is rising internationally [1]. As BMI
increases, so too does the prevalence of co-morbid con-
ditions including diabetes, cardiovascular disease (CVD)
and some cancers [2]. Rising medical costs are a matter
for concern globally, and many attempts have been made
to estimate the costs associated with the increasing preva-
lence of both overweight and obesity [3-8]. This review
examines the literature that has focussed on both the dir-
ect and indirect costs of overweight and obesity.
The healthcare costs associated with obesity are typic-
ally calculated using two main approaches, a top down
method based on estimation of population attributable
fractions (PAF method) and two “bottom up” methods,
based on analyses of cross-sectional and longitudinal
datasets respectively. Other methods such as simulation
modelling can also be used to estimate costs of over-
weight and obesity, however this review will focus on
the PAF method and analyses of cross-sectional and lon-
gitudinal datasets. The PAF method is based on the use
of nationally available prevalence data for obesity and/or
overweight, to which relative risk estimates for the rele-
vant co-morbid conditions are applied, thereby produ-
cing estimates of the population attributable fraction
(PAF) for each condition. The PAFs are applied to na-
tional cost data for the relevant conditions to give an
overall estimate of the cost of overweight and obesity.
Bottom up approaches draw on existing individual level
data from cross-sectional datasets or from longitudinal
studies to link BMI measurements with data on health
care utilisation patterns and or sickness related absen-
teeism [9-12]. The issue of presenteeism is also import-
ant to consider when calculating the cost of overweight
and obesity. Presenteeism refers to a situation in which
the employee remains in the workforce but their prod-
uctivity is adversely affected by their health condition –
for example as a result of their mobility being reduced.
The additional service utilisation associated with over-
weight and obesity is determined by multivariate reg-
ression analysis and monetised using cost data for the
country concerned. The longitudinal approach may pro-
vide the most accurate estimates of the cost of over-
weight and obesity as the occurrence of health outcomes
and sickness related absenteeism is measured directly in
a group of individuals who are followed over time. How-
ever, such data are rare and resource intense in col-
lection, the duration of follow-up required to accrue
sufficient events is typically in decades and participants
in longitudinal cohort studies are often poorly represen-
tative of the wider population, thereby constraining the
generalisability of the findings.
There is now an extensive literature on the cost of
obesity. Many of the early cost of obesity studies used aprevalence based top down PAF approach. However bot-
tom up approaches have been used more widely in recent
years. There are numerous factors which have resulted in
considerable heterogeneity existing within the literature
on cost of obesity studies, including:
 The scope of studies varies with some estimating the
cost of obesity alone and some including the cost of
overweight. Variation is also evident with respect to
the number of conditions included, for example,
which ranged from four [9,10], to ten or more
[11,12].
 Direct healthcare costs are most commonly
calculated, although some studies also include
indirect costs, mainly based on productivity losses
due to illness and disability and early mortality. Even
within the direct healthcare cost there is variation
between studies, with some addressing a wide range
of therapies and others narrowly focussed on a
single aspect, e.g. drug costs [13] or hospital costs
[14,15].
 Different approaches are taken to the presentation
of estimated costs. These include absolute figures in
the currency of the country, the proportion of the
national expenditure on healthcare that can be
attributed to overweight/obesity or relative per
capita spend by BMI category. In the early 1990s,
the World Health Organisation (WHO) categories
for BMI of underweight, normal weight, overweight
and obese were not agreed or consistently applied
internationally. Thus in the earlier studies there is
also variation in the BMI categories used to describe
overweight and obesity.
 The perspective of the studies differ as each country
has a different healthcare system, with various
“bundles of basic care”, range of services and the
balance between public and private sector funding
for health care.
These factors hinder international comparisons in cost
of overweight and obesity studies. In 1997 however, the
WHO standardised the definition of normal weight, over-
weight and obesity [16], and most studies after 1997 have
adopted these definitions.
Many studies of the cost of obesity have been carried
out in the US. This is unsurprising given the scale of the
problem (over 60% of the US population are either over-
weight or obese [17]) and the availability of detailed da-
tabases to support research on the subject. The latter
include the National Health and Nutrition Examination
Survey (NHANES) which was established in the 1970s
and provides data on BMI prevalence and trends over
time. Other databases include the Medical Expenditure
Panel Survey (MEPS) which provide data on healthcare
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American civilian population. Estimates from the 1990
suggested that in the US between 4.3% [18] to 7.8% [19]
of total healthcare expenditure could be attributed to
obesity. Early studies from other jurisdictions include
Australia [20], New Zealand [21], Canada [11], France
[12,22], The Netherlands [23] and the UK [24]. Direct
healthcare costs were the main focus of many of these
studies [11,20-24], mainly using the top down approach
[11,12,20,21,23] and most focussed only on obesity
[11,12,20-22,24]. Of those studies presenting their re-
sults as a percentage of healthcare expenditure, the
range was from 1% [24] to 4% [23], being generally lo-
wer than the values calculated in the US studies. Due to
the inconsistencies highlighted above, cross country
comparisons are difficult. However it would appear that
the proportion of healthcare costs attributable to over-
weight and/or obesity in the US is somewhat higher
than in other developed countries.
While a number of reviews have been published
[3-8,25-30] it is important in the context of a rapidly
emerging evidence base that these are updated on a
regular basis. These previously published reviews have
attempted to assimilate large amounts of data from het-
erogeneous studies which greatly limits the extent to
which conclusions or recommendations can be drawn
from them. This review attempted to examine a more ho-
mogenous group of studies which investigated both the
direct and indirect costs of overweight and obesity and if
comparability of such studies can be improved by redu-
cing the scope of the search strategy. Therefore this review
explores the problems associated with the methodological
heterogeneity of these types of studies, even within the
narrow scope of this review. There is a substantial lack of
literature examining the full scope of costs associated with
overweight and obesity. As a means to address literature
gap and add to the current body of evidence, this review
attempts to reveal the most appropriate methodologies for
these studies and the most appropriate data sources to be
used which would enable international comparisons.
This review formed part of the preliminary work for
the Irish cost of overweight and obesity study which esti-
mated the direct and indirect costs for overweight and
obesity in Ireland for 2009. The study began in 2011 and
was completed in September 2012. Preliminary work for
this study included a broader look at literature estimat-
ing the cost of overweight and obesity. Literature which
was published after 2001 and up to the end of 2011 was
examined and this timeframe is reflected in the search-
ing and identification of relevant papers for the current
review [31]. Articles published prior to 2001 were not
eligible for inclusion as economic data which is older
than ten years bares little relevance in the changing eco-
nomic climate.Methods
Data sources and search strategy
This review has been guided by the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses) statement. An extensive search of the literature
was conducted using the PubMed, EMBASE, CINAHL,
Science Direct, and ProQuest databases to identify rele-
vant studies. Various combinations of the terms ‘cost’,
‘overweight’ and ‘obesity’ were used, and these terms were
expanded for a full MESH search of PubMed. In order to
provide a thorough breakdown of articles according to
scope, two main searches were conducted in PubMed.
The first search focused on the direct cost of overweight
or obesity, with the second search focusing on the indirect
cost of overweight and obesity.
Search 1: Included a MeSH search of the following
search terms: (Overweight OR Obesity OR Obesity, Ab-
dominal OR Anti-Obesity Agents OR Obesity, Morbid
OR Abdominal obesity metabolic syndrome OR Anti-
Obesity Agents) AND (Costs and Cost Analysis OR Eco-
nomics OR economics OR Cost-Benefit Analysis OR
Cost Allocation OR Cost of Illness OR Cost Control OR
Health Care Costs OR Direct Service Costs OR Hospital
Costs OR Employer Health Costs OR Drug Costs).
Search 2: In PubMed a MeSH search of the following
search terms: (Overweight OR Obesity) AND (Cost OR
Absenteeism OR Presenteeism OR Productivity OR Sick
Leave OR Illness Benefit OR Cost to Employer OR
Workers’ Compensation OR Disability OR Premature
Mortality).
The search in CINAHL used the terms ‘obesity and
cost’ or ‘overweight and cost’ and the search in EMBASE
was searched using the terms ‘overweight’ or ‘obesity’
and ‘cost’. Science Direct was searched using the terms
‘overweight’ or ‘obesity’ and ‘cost*’ included in the title,
abstract or as a keyword in the article. The search in
ProQuest used the terms ‘overweight and cost*’ or ‘obes-
ity and cost*’. Reference lists of retrieved articles were
fully scanned and a thorough search of the grey litera-
ture was conducted to include national reports relating
to the cost of overweight and obesity.
Furthermore Conference Proceedings was searched for
unpublished abstracts. Government websites for the ma-
jor developed countries were searched to identify rele-
vant reports; this was augmented with a Google search.
The Cochrane Library was also searched for cost of
obesity studies. Reference lists of retrieved reports and
articles were scanned to identify any further potential
studies that had been missed. Review articles were iden-
tified and while they did not form part of the review,
their reference lists were searched for further unidenti-
fied articles.
Limits applied to the search strategy include; studies
published from 2001 to end of 2011; English language;
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toral Dissertation, Journal Article, Masters Thesis, Meta-
Analysis, Proceedings, Review and Systematic Review. No
restrictions were placed on the study population national-
ity, or statistical designs or methods.
Eligibility criteria
Studies generated from the search strategy were deemed
eligible for inclusion in the review if they satisfied all of
the strict exclusion criteria which included:
1. Studies focused on children and other discreet
groups (e.g., women only, truck drivers etc.).
Children were excluded as they are not included in
the Irish cost of overweight and obesity study for
which this literature review was performed.
2. Studies published before 2001 or after 2011.
3. Studies reporting small study populations (cohort
size <500 overweight or obese persons).
4. All commentary and review articles.
5. Studies which did not measure BMI by the WHO
standard measures as this would make comparisons
very difficult.
The results were summarised and presented in each
case as the costs determined in the study, and these costs
were also converted to 2009 Irish Euros using inflation
rates and Purchasing Power Parity (PPP) in order to im-
prove comparability.
Results
Search strategy results
From PubMed 3481 articles were retrieved from the
combined searches. The combined additional searches
of EMBASE, CINAHL, Science Direct, and ProQuest
yielded 4249 articles. Following removal of duplicates
there were 2283 articles to be reviewed. Following review
by title, 2042 articles were deemed ineligible. The ab-
stracts of the remaining 241 articles were then reviewed
and assessed for inclusion. This resulted in 194 articles be-
ing excluded and the full text of 45 reports and articles on
the cost of overweight and/or obesity were accessed and
read in detail to determine eligibility. Following full text
review, 38 studies were excluded according to the speci-
fied eligibility criteria.
The breakdown of articles by scope was direct costs of
obesity (6 studies), direct costs of overweight and obesity
(22 studies), direct and indirect costs of obesity (7 stud-
ies), direct and indirect costs of overweight and obesity
(7 studies) and indirect costs only (3 studies). Only those
studies that addressed the direct and indirect costs of
both overweight and obesity were included in this re-
view. In total, 7 studies attempted to estimate the direct
and indirect costs of overweight and obesity [32-38]. Ofthese, two did not measure indirect costs, looking in-
stead at transfer payments [34], and out of pocket ex-
penses [38]. These were excluded, leaving only 5 articles
published since 2001 estimating the direct and indirect
costs of overweight and obesity. This search strategy is
outlined in Figure 1.
Measuring direct and indirect costs
Three studies used the top down approach of calculating
PAFs for both direct and indirect costs [32,36,37]. Two
of these studies [32,36] applied the human capital ap-
proach to calculating the indirect costs. This approach
estimates the value of lost production as a result of work
absences from the employees’ perspective. Output lost is
valued using the individual’s work related income and
the full duration of their absence from the workplace.
The third study, that of Schmid and colleagues provides
little detail on how indirect costs were calculated [37].
Finklestein et al. in the US used a cross-sectional ap-
proach to both direct and indirect costs [35] whereas
Borg et al. [33] used data from a longitudinal cohort,
Of the studies that used the PAF methodology
[32,36,37] all three included a wide range of co-morbid
illnesses, but the calculated attributable fractions dif-
fered for each study. Anis et al. [32] calculated PAFs for
both overweight and obesity and for males and females
separately. Konnopka et al. [36] calculated PAFs for males
and females separately, but combine overweight and obes-
ity, while Schmid et al. [37] calculate PAFs separately for
overweight and obesity but combine males and females.
All three studies included a wide range of activities in the
direct cost calculation, including inpatient, outpatient and
pharmaceutical costs, details of which are outlined in
Table 1.
There is further variation in the calculation of indirect
costs. Two of the studies [32,36] applied the human ca-
pital approach to calculating the indirect costs. Output
lost is valued using the individual’s work related income
and the full duration of their absence from the work-
place. The third study, that of Schmid and colleagues
provides little detail on how indirect costs were calcu-
lated [37]. While Anis et al. [32] measure long and short
term disability, Konnopka et al. [36] also measure early
retirement and premature mortality. The latter also in-
clude paid and unpaid work in their calculation of indir-
ect costs. Schmid et al. [37] measure sickness absence,
early retirement and premature mortality productivity
losses, but the methodology used in this part of the
study is unclear.
While the results for the Canadian study [32] and the
German study [35] are remarkably similar in terms of
absolute costs, Table 1, it must be remembered that the
population of Germany is over twice that of Canada (82
million vs. 33 million). Thus it would appear that the
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disproportionately high. However this most likely re-
flects differences in the two healthcare systems and
methodological differences between the two studies. The
Canadian estimates were based on BMI prevalences de-
rived from measured height and weight whereas the
source of the BMI data in the German study is unclear.
The findings from Switzerland (population 7 million) are
broadly proportionate with those from Germany.
For Sweden, Borg et al. [33] estimated direct costs
based on hospital inpatient costs only and indirect costs
were estimated on the basis of lost productivity due to
increased mortality. They studied a longitudinal cohort
of adult men and women from the Malmö Prevention
Project, enrolled between 1974 and 1984 and followed
up for 15 years. BMI was based on measured height and
weight in study subjects. Using a stepped regression
modelling technique, they estimated costs for the normalweight, overweight and obese groups. They found no
major differences in hospital usage between the over-
weight and normal weight groups and consequently
there were no significant costs differences between these
groups. By contrast there were significant cost differences
between normal weight groups and obese groups. Simi-
larly, when looking at the lost productivity and associated
costs, the main differences lay between the obese group
and the others and there was little difference between the
overweight and normal weight groups. Notably, the study
did not include drug or other healthcare costs in the esti-
mate of costs. The low costs estimated in this study reflect
the size of the Swedish population (9 million) and the lim-
ited scope of the study which was confined to hospital
costs and premature mortality. However these estimates
derived from a longitudinal cohort study are arguably
closer to reality than those derived from top down estima-
tions of population attributable fractions.
Table 1 Direct and indirect costs of overweight and obesity
Study Costs included direct Cost included indirect Type of study Results direct Results indirect Results total (€ 2009) Percentage of
results that are
indirect
Anis et al. 2010
[32], Canada
Hospital inpatient and outpatient visits,
physician services, drug costs, health
research and other health care
Morbidity due to both long
and short-term disability
Prevalence
based PAF
CA$5.96 billion CA$5 billion $10.96 billion (€7.3
billion 2009)
54%
Konnopka et al.
2011 [36], Germany
Inpatient and outpatient treatment,
rehabilitation and non-medical costs
(administration, research etc)
Sickness absence, early
retirement and mortality using
human capital approach
Prevalence
based PAF
€4.854 billion (2.1%
of total healthcare
costs for 2002)
€5.019 billion €9.873 billion (€11.01
billion 2009)
51%
Schmid et al. 2004
[37], Switzerland
All healthcare costs for obesity and co-
morbid conditions
Work absenteeism, early
retirement and premature
death relating to co-
morbidities
Prevalence
based PAF
N/A N/A CHF2.69 billion (€1.91
billion 2009)
N/A
Finkelstein et al.
2010 [35], US
All Medical costs absenteeism and presenteeism Cross-sectional $30.3 billion $42.8 billion $73.1 billion (€51.92
billion 2009)
59%
Borg et al. 2005
[33], Sweden
Hospital inpatient costs only Lost productivity due to
increased mortality
Longitudinal
cohort
SEK Billion: 2.17 SEK Billion: 2.93 SEK billion: 5.1 (€0.54
billion 2009)
58%
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from MEPS (for healthcare costs) and the National
Health and Wellness Survey (NHWS) (for data on ab-
senteeism and presenteeism) to estimate costs on a cross
sectional basis. BMI was based on self-reported data. For
direct costs they measured all healthcare use, and for in-
direct costs they measured absenteeism and presentee-
ism as determined in self-reported responses in the
NHWS. They found that for all categories of obesity, the
three variables: healthcare costs, absenteeism and pres-
enteeism all increased with increasing BMI. These find-
ings did not apply to overweight men, who had lower
rates of presenteeism than their normal weight counter-
parts. They also found that although people with a BMI
> 35 kg/m2 represent only 37% of all obese people in the
US, they account for 61% of the costs. Presenteeism was
found to be a stronger driver of costs associated with
lost productivity than was absenteeism. The US cost es-
timates are high, reflecting their population size , but
they are consistent with those from Germany [36].
Table 1 provides a breakdown of the five studies. Indir-
ect costs were higher than direct costs in all four of the
five studies which presented separate estimates for direct
and indirect costs.
Discussion
Healthcare costs increase as BMI increases, and so do
costs associated with lost productivity. The costs associ-
ated with lost production are higher than direct health-
care costs. There is a substantial international literature
on the question of the costs associated with weight gain
but review and synthesis of this literature are hindered
by the heterogeneity of the studies in terms of scope,
data sources, data quality and methodological approa-
ches. This was evident even within the small number of
studies that met the criteria for inclusion in this review.
The available evidence suggests that increasing BMI is
associated with increased healthcare consumption and
reduced productivity. While the risk of co-morbidity is
greatest in the obese segment of the population (ap-
proximately 25% of adults in many developed countries)
there is a graded relation between BMI and major causes
of co-morbidity. Therefore it may be deduced that the
additional larger segment of the population who are over-
weight (approximately 40% of adults in developed coun-
tries) would be the main driver of costs. Based on current
evidence, this is not the case. It is also clear that the per
capita costs increase as BMI increases, with obesity ac-
counting for much higher costs than overweight. In Borg
et al’s longitudinal study in Sweden, obesity was the main
driver of costs [33]. Similarly, Finklestein et al. found that
healthcare costs, absenteeism and presenteeism were all
increased in the obese whereas costs in overweight men
were not increased relative to those of normal weight [35].Estimation of the costs of illness based on population
attributable fractions poses particular difficulties. The
outputs from this exercise depend critically on four core
inputs which vary considerably in the precision of esti-
mates and the inclusion criteria applied in different stud-
ies: the estimated prevalence of overweight and obesity,
the list of co-morbid conditions linked to overweight
and obesity, the relative risk estimates used to calculate
PAF’s and the availability and quality of national cost
data. There are additional concerns in relation to the
PAF based approach, including the problem of double
counting due to multi-morbidity. Double counting is an
issue associated with the second of the core inputs out-
lined previously. It is imperative that diagnoses of the
same health issue (co-morbid condition) associated with
overweight and obesity are grouped into one episode of
care to avoid double counting. While these studies may
have some merit in highlighting for policy makers the
relative scale of specific problems and the need for
investment in prevention, the heterogeneity evident in
this narrowly focused literature review raises important
questions on the validity and reliability of this approach.
The analysis of cross-sectional datasets offers a more
promising avenue of investigation. Most developed coun-
tries now carry out regular national health and lifestyle
surveys to monitor the health and wellbeing of the po-
pulation and assess the impact of public health policies
and interventions [39,40]. These cross-sectional studies
involving relatively large and representative samples of
adults provide valuable opportunities to measure BMI
and other measures of body fat with linked data on
health care utilisation in primary and secondary care,
absenteeism and presenteeism during the preceding
year. The development and standardisation of mini-
mum datasets for cost of illness studies drawing on
national health and wellbeing surveys would represent
a significant advance in this area. Ideally, analyses of
cross sectional data from representative population sam-
ples should be supplemented with high quality routine
primary care data and data from longitudinal studies on
incident disease and mortality. Theoretically the use of
longitudinal data with measured BMI and data on mor-
bidity, health care utilisation, mortality and productivity
loss offer the best opportunity for obtaining good quality
data on the costs of overweight and obesity. In practice
however for most countries worldwide, the relevance,
quality and timeliness of cost of illness data from longitu-
dinal studies is limited.
A number of conclusions may be drawn on the esti-
mation of indirect costs. Presenteeism is rarely mea-
sured. It was addressed in only one of the studies [35]
included in this review and in few studies in the wider
literature [41,42]. As the concept of presenteeism is in-
herently subjective the findings in relation to this issue
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need for ongoing work on the development and valid-
ation of appropriate instruments in this area. By con-
trast, absenteeism is easier to measure and more likely
to be verifiable from alternative datasets (e.g. social
welfare data, hospital in-patient days), making it a more
useful marker of lost productivity. Premature mortality
was measured in only three of the studies [33,36,37], all
of which used different methods. Despite the methodo-
logical weakness and inconsistencies of these studies it
noteworthy however in the four studies which presented
separate estimates for direct and indirect costs, indirect
costs were higher, accounting for between 54% and 59%
of the estimated total costs.
A limitation of this review is the narrow eligibility cri-
teria for inclusion of studies. As the objective of this
study was to review studies which focused on both dir-
ect and indirect costs only, the scope of the search strat-
egy was significantly narrower. However, the dearth of
literature examining the full scope of costs associated
with overweight and obesity is an additional factor to
this limitation. Further to this paucity of literature, the
absence of international standardised methods and a
lack of consensus in the design of these cost of over-
weight and obesity studies, hinders the completion of a
comprehensive review.Conclusion
While cost of overweight and obesity studies are helpful
for health program planning in terms of quantifying
the magnitude of the problem and setting funding
priorities it is clear that the results of these studies
merit cautious interpretation, particularly with regards
how best to tackle the problem. Furthermore these
studies need to be considered within the broader con-
text of work on the relative cost-effectiveness of potential
policies, programmes and interventions addressing the
ongoing epidemic of overweight and obesity in children
and adults. In conclusion, there is a consensus that as
BMI rises, so too do both the direct healthcare costs and
the indirect costs due to reduced productivity and early
mortality. A more precise quantification of the increase in
costs is hindered by the heterogeneity in the evidence-
base even when studies with a similar scope are consid-
ered. To improve the quality of information available for
policy and planning purposes, greater standardisation is
required both in methodological approach and reporting.
Moreover, while top-down studies are of value in the
absences of other data, it is likely that investment in
high-quality, bottom-up cross-sectional and longitu-
dinal studies will be needed to better understand the
main drivers of costs and target prevention strategies
and/or interventions most appropriately.Key points
 Heterogeneity is a major limitation in the cost of
overweight and obesity literature.
 Bottom up approaches to cost of obesity studies
help to identify the main drivers of cost and
therefore can inform focussed public health
interventions.
 While cost of overweight and obesity studies are
useful to highlight the scale of the problem, they
need to be set within the wider context of work on
the relative cost-effectiveness of potential policies,
programmes and interventions.
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